Related Experiment Video
Updated: Jun 29, 2026
06:46
A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
Published on: July 5, 2022
Recent and emerging anti-diabetes targets.
Michael L Mohler1, Yali He, Zhongzhi Wu
1Preclinical Research and Development, GTx, Inc., 3 N. Dunlap Street, Memphis, TN 38163, USA. mmohler@gtxinc.com
Medicinal Research Reviews
|October 16, 2008
Summary
New diabetes treatments are urgently needed as current medications fail to control blood sugar long-term. This study presents 20 emerging targets for novel small molecule therapies to combat rising diabetes rates and severe complications.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Diabetes affects over 150 million globally, with increasing prevalence due to obesity and sedentary lifestyles.
- Current oral and injectable diabetes medications often fail in long-term glycemic control, even in combination therapy.
- Inadequate glycemic control leads to life-threatening complications like cardiovascular disease, blindness, kidney issues, and amputations.
Purpose of the Study:
- To address the critical need for more potent pharmacotherapies for diabetes.
- To identify and discuss novel mechanisms of action for diabetes treatment.
- To present a panel of 20 emerging diabetes targets.
Main Methods:
- Identification of 20 emerging molecular targets implicated in diabetes pathogenesis.
- Review and discussion of small molecule modulators for each identified target.
Main Results:
- A curated list of 20 promising molecular targets for diabetes intervention.
- Overview of potential small molecule drug candidates for these targets.
Conclusions:
- There is a significant unmet need for advanced diabetes pharmacotherapies.
- Emerging targets and their small molecule modulators offer potential for improved long-term glycemic control.
- Novel therapeutic strategies are essential to mitigate severe diabetes-related complications.
Related Concept Videos
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:26Diabetes Mellitus: Introduction
Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...
01:15Diabetes: Symptoms, Diagnosis, and Complications
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...